
NYSEHealthcareMedical - Devices
ข้อมูลล่าสุด
US$42.73
+US$0.69 · +1.64%
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
ราคาปิดก่อนหน้า
US$42.73
+US$0.69 · +1.64%
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
ช่วงราคารายวัน
ปัจจุบัน US$42.73
ช่วง 52 สัปดาห์
ปัจจุบัน US$42.73
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ซื้อ
มูลค่า
95
มูลค่าน่าสนใจมาก
ความเชื่อมั่น
77
เชิงบวก
ความเสี่ยง
50
ความเสี่ยงค่อนข้างสูง
โมเมนตัม
24
กำลังอ่อนตัว
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
ช่วงราคารายวัน
ปัจจุบัน US$42.73
ช่วง 52 สัปดาห์
ปัจจุบัน US$42.73
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 20.07B USD | 16.75B USD | 14.24B USD | 12.68B USD | 11.89B USD |
| ต้นทุนสินค้าขาย | 6.22B USD | 6.48B USD | 5.41B USD | 4.97B USD | 4.43B USD |
| กำไรขั้นต้น | 13.85B USD | 10.27B USD | 8.83B USD | 7.71B USD | 7.46B USD |
| การวิจัยและพัฒนา | 2.05B USD | 1.62B USD | 1.41B USD | 1.32B USD | 1.2B USD |
| การขาย ทั่วไป และธุรการ | 6.89B USD | 5.98B USD | 5.19B USD | 4.52B USD | 4.29B USD |
| ค่าใช้จ่ายในการดำเนินงาน | 9.88B USD | 7.63B USD | 6.65B USD | 5.89B USD | 5.54B USD |
| รายได้ดอกเบี้ย | — | 107M USD | 22M USD | 10M USD | 4M USD |
| ดอกเบี้ยจ่าย | 349M USD | 387M USD | 272M USD | 464M USD | 349M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 1.37B USD | 1.27B USD | 1.2B USD | 1.14B USD | 1.09B USD |
| รายได้จากการดำเนินงาน | 3.97B USD | 2.64B USD | 2.18B USD | 1.82B USD | 1.92B USD |
| รายได้สุทธิ | 2.89B USD | 1.85B USD | 1.59B USD | 698M USD | 1.04B USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 11 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$62.71
โอกาสปรับขึ้น 46.76%ไม่มีประวัติราคา
สูง: US$100เฉลี่ย: US$62.71ต่ำ: US$48.00กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
State Street SPDR S&P 500 ETF1557.T117.49B0.09%129.35T JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI2.28B0.10%2.3T USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO1.91B0.11%1.8T USD0.03%US$715.59+0.61%
iShares Core S&P 500 ETFIVV809.91M0.09%896.44B USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY742.23M0.09%817.2B USD0.09%US$778.57+0.60%
Vanguard Morningstar Growth ETFVUG440.93M0.11%384.6B USD0.03%US$91.97+0.72%
State Street Health Care Select Sector SPDR ETFXLV433.89M1.00%43.54B USD0.08%US$170.81+1.58%
Vanguard Morningstar Value ETFVTV342.99M0.13%262.4B USD0.03%US$220.59+0.44%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Growth ETFVUG
State Street Health Care Select Sector SPDR ETFXLV
Vanguard Morningstar Value ETFVTVเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน